| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Wound Healing and Glaucoma Research Units, Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom; and 2Cambridge Antibody Technology, Cambridge, United Kingdom.
PURPOSE. Postoperative subconjunctival wound healing remains the commonest cause of late bleb failure after glaucoma filtration surgery. This study was undertaken to investigate whether the human monoclonal antibody that neutralizes transforming growth factor-ß2 (CAT-152; lerdelimumab) could be used as a postoperative agent to prevent scarring after glaucoma surgery and compared it with 5-fluorouracil (5-FU), to benchmark its potential clinical benefit.
METHODS. In a randomized, controlled, masked-observer study, after modified glaucoma surgery, 48 rabbits were randomly allocated to receive a postoperative course of seven subconjunctival injections of CAT-152 (1 mg/mL), 5-FU (50 mg/mL), or no treatment. Bleb characteristics, the presence of subconjunctival drainage, and local reaction to treatment were assessed. Animals were killed on days 10, 21, and 30. Immunohistochemistry, histologic staining and electron microscopy were performed to demonstrate the mechanism of CAT-152–mediated effects on the extracellular matrix.
RESULTS. CAT-152 significantly improved surgical outcome (log rank test, P < 0.001) and reduced subconjunctival collagen deposition (P < 0.01) compared with 5-FU and control. Median bleb survival was increased in the CAT-152 group (23.5 days) compared with the 5-FU (20 days) and control (16 days) treatment groups. CAT-152 treatment improved bleb morphology (P < 0.05) and was well tolerated. 5-FU prolonged the duration of corneal epitheliopathy (P < 0.01).
CONCLUSIONS. Postoperative administration of CAT-152 significantly improved surgical outcome, reduced subconjunctival scarring, and minimized the risk of corneal side effects compared with the anti-scarring agent 5-FU. These findings suggest that CAT-152 may offer therapeutic benefit as a postoperative agent to prevent subconjunctival scarring after glaucoma filtration surgery.
This article has been cited by other articles:
|
|
 |
|
  Y. Liu, J.-A. Ko, R. Yanai, K. Kimura, T.-i. Chikama, T. Sagara, and T. Nishida Induction by Latanoprost of Collagen Gel Contraction Mediated by Human Tenon Fibroblasts: Role of Intracellular Signaling Molecules Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1429 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Honjo, H. Tanihara, T. Kameda, T. Kawaji, N. Yoshimura, and M. Araie Potential Role of Rho-Associated Protein Kinase Inhibitor Y-27632 in Glaucoma Filtration Surgery Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5549 - 5557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. LaGier, S. H. Yoo, E. C. Alfonso, S. Meiners, and M. E. Fini Inhibition of Human Corneal Epithelial Production of Fibrotic Mediator TGF-{beta}2 by Basement Membrane-Like Extracellular Matrix Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1061 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Priglinger, C. S. Alge, D. Kook, M. Thiel, R. Schumann, K. Eibl, A. Yu, A. S. Neubauer, A. Kampik, and U. Welge-Lussen Potential role of tissue transglutaminase in glaucoma filtering surgery. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3835 - 3845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Zhao and F. M. Hoffmann Inhibition of Transforming Growth Factor-beta1-induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARA Mol. Biol. Cell, September 1, 2006; 17(9): 3819 - 3831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146. [Full Text] [PDF]
|
|
|
|
|
|
T. T. L. Wong, A. L. Mead, and P. T. Khaw Prolonged Antiscarring Effects of Ilomastat and MMC after Experimental Glaucoma Filtration Surgery Invest. Ophthalmol. Vis. Sci., June 1, 2005; 46(6): 2018 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Eibl, B. Banas, D. Kook, A. V. Ohlmann, S. Priglinger, A. Kampik, and U. C. Welge-Luessen Alkylphosphocholines: A New Therapeutic Option in Glaucoma Filtration Surgery Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2619 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. LEASK and D. J. ABRAHAM TGF-{beta} signaling and the fibrotic response FASEB J, May 1, 2004; 18(7): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
